RenovoRx to Present at the ROTH MKM Healthcare Opportunities Conference on October 12, 2023
02 Oktober 2023 - 2:30PM
Business Wire
RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a
clinical-stage biopharmaceutical company developing targeted
combination therapies, today announced that CEO, Shaun Bagai, will
present at the ROTH MKM Healthcare Opportunities Conference in New
York on October 12, 2023. Register here.
Moderated by Scott Henry, Managing Director, Senior Research
Analyst & Head of Pharmaceuticals Research at ROTH Capital
Partners, LLC, will conduct a fireside chat with Mr. Bagai, who
will discuss recent Company milestones, including the research
collaboration with Imugene (ASX: IMU), and highlights from
RenovoRx’s open label pivotal Phase III TIGeR- PaC study.
ROTH MKM Healthcare Opportunities
Conference Date: October 12, 2023 Time:
11:30 AM ET Speaker: Shaun Bagai, CEO Location: The
Yale Club, New York City Register:
https://www.meetmax.com/sched/event_95633/conference_register.html
To schedule a one-on-one investor meeting with RenovoRx’s
management team, please contact your ROTH MKM representative or
KCSA Strategic Communications at RenovoRx@KCSA.com.
About RenovoRx, Inc.
RenovoRx is a clinical-stage biopharmaceutical company
developing proprietary targeted combination therapies for high
unmet medical need with a goal to improve therapeutic outcomes for
cancer patients undergoing treatment. The Company’s proprietary
Trans-Arterial Micro-Perfusion (TAMPTM) therapy platform is
designed to ensure precise therapeutic delivery to directly target
the tumor while potentially minimizing a therapy’s toxicities
versus systemic (intravenous (IV) therapy). RenovoRx’s unique
approach to targeted treatment offers the potential for increased
safety, tolerance, and improved efficacy. Our Phase III lead
product candidate, RenovoGemTM combines gemcitabine with a patented
delivery system. It is currently being investigated under a US IND
that is regulated by FDA 21 CFR 312 pathway. RenovoGem is currently
in a Phase III clinical trial (TIGeR-PaC) for the treatment of
locally advanced pancreatic cancer (LAPC).
RenovoRx is committed to transforming the lives of patients by
delivering innovative solutions to change the current paradigm of
cancer care. RenovoGem is currently under investigation for TAMP
therapeutic delivery of gemcitabine and has not been approved for
commercial sale.
For more information, visit www.renovorx.com. Follow RenovoRx on
Facebook, LinkedIn and Twitter.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231002933517/en/
Investor Contact: KCSA Strategic Communications Valter
Pinto or Jack Perkins T: 212-896-1254 renovorx@kcsa.com
Media Contact: KKH Advisors Kimberly Ha T: 917 291-5744
kimberly.ha@kkhadvisors.com
RenovoRx (NASDAQ:RNXT)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
RenovoRx (NASDAQ:RNXT)
Historical Stock Chart
Von Jun 2023 bis Jun 2024